Capricor Therapeutics, Inc. (CAPR) vs NeoGenomics, Inc. (NEO)
A side-by-side comparison of Capricor Therapeutics, Inc. and NeoGenomics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CAPR
Capricor Therapeutics, Inc.
$7.66HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
NEO
NeoGenomics, Inc.
$16.72HealthcareDelayed quote: Oct 6, 2026, 12:50 PM EDT
Total return — CAPR vs NEO
growth of $100 · dividends reinvested · last 10yCAPR -75.8% (-13.2%/yr)NEO +134.5% (+8.9%/yr)NEO compounded faster over this window
Log scale — wide-divergence pair
CAPR NEO
CAPR vs NEO: by the numbers
- •CAPR is the larger company ($441M vs $430M market cap).
- •Both run net losses; CAPR's is the smaller (0.00% vs -6.77% net margin).
Metrics side by side
Valuation
| Metric | CAPR | NEO |
|---|---|---|
| Forward P/E | N/A | 91.50 |
| P/S ratio | N/A | 0.56 |
| P/B ratio | 1.79 | 0.55 |
| EV / EBITDA | 0.44 | N/A |
Profitability
| Metric | CAPR | NEO |
|---|---|---|
| Gross margin | 0.00% | 42.92% |
| Operating margin | 0.00% | -8.63% |
| Net margin | 0.00% | -6.77% |
| ROE | -52.56% | -6.60% |
| ROIC | -40.25% | -5.29% |
Growth (annualized)
| Metric | CAPR | NEO |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 9.41% |
| Total return CAGR (5Y) | 15.17% | -15.14% |
Frequently asked
- How have CAPR and NEO total returns compared?
- Over the past 10 years, CAPR delivered -13.84% and NEO delivered 8.90% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.